You are here

GST (Flanders) acquired by Boehringer Ingelheim (DE)

After two years of successful cooperation, Boehringer Ingelheim has acquired GST, Flanders-based stem cell specialist focusing on horses and pets. As part of the independent laboratory group Anacura, GST will continue its innovative research and production at its existing labs in Ghent. GST’s expertise will play a crucial role in the development and implementation of stem cell technology worldwide. 

Backed by knowledge and experience

'Global Stem Cell Technology' (GST) develops stem cell therapies for the treatment of orthopedic and metabolic diseases in animals. Within Europe, the company was the first to obtain authorization to market veterinary medicines based on stem cells worldwide. Along with an investment by Participatie Maatschappij Vlaanderen (PMV), GST was incorporated into the Anacura group of Griet Nuytinck in 2014. “This was more than a financial investment in a startup,” explains Nuytinck. “We offered GST support from an experienced biotech business environment, at a time when stem cell therapy was still an unexplored and unclear area.” 

Innovation to the core

Thanks to its deep commitment to developing effective and standardized products and with the logistical support of Boehringer Ingelheim, GST became a forerunner in its field. “The recent takeover opens up possibilities for developing and selling new stem cell products all over the world,” ascertains Nuytinck. According to Jean-Luc Michel, head of Global Strategic Marketing at Boehringer Ingelheim, GST’s expertise and state-of-the-art products will enable the firm to offer even more innovative solutions to customers. 

Dream scenario for stem cell platform in Flanders

Nuytinck is thrilled with the news of the acquisition. She is convinced that GST CEO Jan Spaas and his team will be given every opportunity to develop their stem cell platform within their new professional environment. “Furthermore, we will continue to embed innovative stem cell research in our laboratories in Flanders.” Roderick Verhelst, senior investment manager at PMV and director of GST adds: It’s a strong recognition of Flanders' position as a global biotech leader.” 

More info

Boehringer Ingelheim
Reported by
7 August 2020

More news about Flanders?

  • Regular updates
  • No spam

Interested in doing business in Flanders?

Let us help you!

  • We can introduce you to other companies, banks and regulators
  • We organize site visits to real estate locations
  • We assist with all legal aspects of setting up a business
  • We're an official government agency
  • Our services are completely free
  • We are a team of international experts

Receive our handbook to growing your business in Flanders

  • It's completely free.
  • Get an overview of all incentives relevant to your company.
  • Tax system explained in-depth.
  • Learn how to set up your business quickly.
  • Discover the benefits of Flanders (in addition to the chocolate).

In addition to the ebook, I agree to receive one or two follow-up emails